Call to Evidence for Access To Medicines Inquiry 2014
Call for evidence- Access to Medicines in the Developing World
APPG enquiry: Achieving Universal Access – The Treatment Timebomb Part II
Deadline for Submissions is Wednesday 19th March 2014, 9am
Background to the Inquiry
In 2009 the All Party Parliamentary Group on HIV and AIDS conducted an inquiry on the supply of affordable anti-retroviral medicines (ARVS), which concluded that the high price of second and third line drugs for HIV was a major barrier to access to HIV treatment. The report was successful in mobilising political support for the Medicines Patent Pool, and in highlighting the “Treatment time bomb” which exists as people in developing countries switch from first line HIV treatment to more expensive second and third line drugs.
Since then there have been significant developments in anti-retroviral treatment, most notably with the results of the HPTN 052 trial which concluded that HIV treatment can be highly effective in preventing the transmission of the disease. There are also a number of new ARV drugs appearing in the market which will likely represent the future of HIV treatment and access to them will become central in the coming years.
In 2011 World leaders agreed to a target at the UN of putting 15 million people on treatment by 2015. However in 2013 the World Health Organisation changed its guidelines to start ARV treatment at an earlier stage in the illness when a person’s CD4 count reaches 500cells/mm3. This means that an estimated 26 million people should be eligible for ARV treatment, making the 2011 UN target of reaching 15 million people less ambitious than previously thought. Another major development since 2009 is the establishment of the Medicines Patent Pool/
For more information please contact the Policy Advisor to the APPG on HIV and AIDS:
Download Guidance for Submissions [218 Kb]